Italy patient information and consent requirements

The governing approach

Consent is a continuing discussion. It begins before enrolment and continues when new information could affect willingness to participate. A signed form records the decision, but it does not replace an understandable explanation, questions, time to consider and confirmation that the participant understood the essential points.

The information must be exhaustive enough for a valid decision, yet concise and relevant. Avoid medical jargon, unexplained acronyms, English terms in an Italian form and statements that waive legal rights. Do not overstate benefit, minimise risk or present reimbursement as an inducement.

Language, accessibility and mediation

Provide participant information and consent in Italian. Adapt it to health literacy, age, decision-making capacity and disability. Use readable type, short sentences and direct headings. A question-and-answer format is acceptable and often useful.

Where a potential participant does not understand Italian, arrange qualified language support and translated material appropriate to that person. The CCNCE guidance identifies a cultural mediator as an appropriate safeguard. Document the process used. A relative's informal summary is not a reliable substitute for accurate information and an impartial consent process.

Electronic consent is possible on a case-by-case basis if the ethics committee approves it and the process complies with the Clinical Trials Regulation, GDPR and GCP. It should preserve direct interaction, identity verification, access to the information, an auditable signature and delivery of a copy.

Recommended document structure

Use a layered form. Start with one or two pages of key information that explains the decision in plain language. Follow with detailed information and then the consent declarations and signatures.

The title block should identify the study title in Italian, a lay title where helpful, protocol or EU trial identifier, sponsor or funder, trial site, principal investigator and competent ethics committee. Institution letterhead is not required. If it is used, it should belong to the institution conducting or hosting the trial, not an unrelated sponsor or vendor.

Key information section

The opening should state that participation is voluntary and that refusal or withdrawal will not affect ordinary care or legal rights. Explain why the person is being invited, the purpose of the research, the investigational nature of the treatment and the main differences from normal care.

Summarise the expected duration, visits, randomisation, placebo or blinding, main procedures, additional samples, major burdens, foreseeable risks, potential benefits and alternatives. State whether there is no expected direct benefit. Include the most important pregnancy, contraception, privacy, reimbursement, injury and contact information without forcing the reader to search the appendices for the decision-critical facts.

Detailed study information

Explain the study design and every participant-facing procedure in a logical sequence. Identify standard-care procedures separately from research-only procedures. Describe blood volume and frequency, imaging, questionnaires, device use, home activities, travel, confinement and follow-up. Where competitive enrolment can close recruitment before the local target is reached, explain that possibility.

Describe known and reasonably foreseeable risks, product-class risks, procedure risks, reproductive risks and material uncertainties. Phase I and first-in-human trials need particularly direct wording about limited human experience and unknown risks. Explain emergency arrangements and whom to contact for urgent medical concerns.

Describe realistic potential benefits and say clearly when benefit is not expected. Explain alternatives, including ordinary treatment and the option not to participate. Cover post-trial treatment or access where relevant, including what is and is not guaranteed.

State participant responsibilities such as attending visits, reporting symptoms and medicines, following contraception measures and returning unused product or devices. Explain circumstances in which the investigator or sponsor can end participation and what follow-up may continue for safety.

Privacy, records and results

The clinical-consent form should explain in plain language that authorised persons may review coded trial data and relevant medical records. Keep the detailed GDPR information and data-processing consent in a separate Italian privacy document, as required by current CCNCE guidance.

Identify who may access records, why access is needed, how confidentiality is protected, whether data leave the European Economic Area and what happens after withdrawal. Do not promise deletion where the sponsor must retain lawfully collected trial data to protect scientific integrity or meet regulatory duties. Explain the right to stop new optional collection prospectively.

Explain whether clinically relevant incidental findings may arise, who assesses them and how they may be communicated. State how overall trial results and, where applicable, an understandable summary will be made available. Describe whether the participant's general practitioner or paediatrician will be informed and obtain any necessary permission.

Costs, reimbursement, injury and contacts

State whether study treatment, tests and visits are free of charge. Describe reimbursement of actual trial-related expenses and any permitted documented loss-of-income arrangement. Avoid the word “payment” if it suggests a reward for accepting risk. All financial arrangements must match the Part II reimbursement document and ethics approval.

Explain trial insurance and the route for reporting suspected injury. Do not require the participant to waive claims. Provide accessible contacts for study questions, urgent medical concerns, participant rights and data protection. Check that phone numbers and service hours are operational at every site.

Biological samples and optional activities

Separate protocol-required sample analysis from optional storage or future research. Italy's current guidance calls for specific, separate information and consent for collection, storage and future use of residual human biological material. Explain the sample type, amount, purpose, coding, location, access, transfer, retention, destruction and limits on withdrawal.

Use separate choices for optional genetic testing, biobanking, future secondary research and optional sub-studies. A refusal must not prevent main-study participation unless the activity is scientifically essential and described as such in the protocol. Use the secondary-use consent guide for the detailed content.

Signature and copy requirements

At the consent visit, the participant and the doctor or investigator who provided the information and obtained consent sign and date the form. Use place, date and time fields where the national model includes them. The investigator's signature should confirm that the discussion occurred, questions were answered and consent was freely given.

Give the participant a copy of the signed and dated documents. Keep the original according to the approved process. If a capable participant cannot write, use an alternative recording method and at least one impartial witness as described in the impartial-witness guide.

Do not pre-sign, backdate or complete participant fields in the CTIS submission copy. Use a controlled blank template with a visible title, language, version and date.

Re-consent and changes

Re-consent when new safety information, a protocol change, a new optional activity or another material fact could affect willingness to continue. Provide the approved new version, allow questions and document the decision. Preserve the sequence of versions in the trial records.

The June 2026 CCNCE FAQ states that an authorised consent form is nationally valid and must not be modified by individual sites. Site corrections, translations and substantive wording changes must be controlled by the sponsor and submitted for ethics approval as a modification when required.

Population-specific routes

Prepare separate, situation-appropriate material rather than forcing every participant through the adult form:

• Healthy-volunteer consent requirements
• Minor consent and assent requirements
• Limited-capacity and legal-representative consent requirements
• Emergency-enrolment consent requirements
• Pregnancy follow-up requirements

Use the Italy Part II checklist to confirm the wider dossier and the patient-facing QC checklist before upload. Return to the Italy CTIS guide hub for the full series.